GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial. The results ...
GSK plc (NYSE:GSK) released headline results from a planned analysis of Part 1 of the RUBY phase 3 trial of Jemperli (dostarlimab) plus standard-of-care chemotherapy (carboplatin and paclitaxel), ...
GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use in endometrial cancer. RUBY ...
· Approval based on RUBY Part 1 trial, which showed a median overall survival (OS) of 44.6 months for Jemperli plus chemotherapy vs. 28.2 months for chemotherapy alone · Jemperli plus chemotherapy is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results